Jeffrey W. Albers - 22 Nov 2023 Form 3/A - Amendment Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role: Director
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol: SYRE
Transactions as of: 22 Nov 2023
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 08 Dec 2023, 16:03:58 UTC
Date Of Original Report: 27 Nov 2023
Previous filing: 03 Nov 2023
Next filing: 28 Nov 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SYRE	Series A Preferred Stock							22 Nov 2023	Common Stock	34,360		By Sessions LLC	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations.

Remarks:

This amendment is being filed to report the shares of Series A Preferred Stock that were beneficially owned by the Reporting Person as of November 22, 2023, which were inadvertently omitted in the original Form 3.